New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Clinical Study Validates the Benefits of Jarrow Formulas® Q-absorb(TM) in Patients with Chronic Heart Failure

Orlando, Florida, Wednesday, November 19, 2003– The results of a clinical trial investigating the effects of Jarrow Formulas® Q-absorb™, an enhanced-absorption CoQ10 formula, on Chronic Heart Failure patients was presented by Dr Romulado Belardinelli at the annual American Heart Association meeting held November 9-12 in Orlando, FL.

Italian scientists from the Lancisi Heart Institute and the University of Ancona (Institute of Biochemistry) measured the effects of 300 mg per day (100 mg T.I.D.) Q-absorb™ on the cardiovascular functional capacity of 23 heart patients. Measurements included endothelial-dependent vasodilation as measured by ultrasound BART (brachial artery reactivity test), plasma ubiquinone, and other important cardiovascular biochemical parameters. In this randomized, placebo-controlled, double-blind, crossover clinical trial, the study results proved the efficacy of Q-absorb™, as demonstrated by:

• improving functional capacity (peak volume of oxygen consumed VO2)
• improvement in endothelial-dependent vasodilation
• tripling of plasma coenzyme Q 10 levels (p<0.0001)

One experimental arm consisted of Chronic Heart Failure patients administered Q-absorb™ plus a prescribed exercise regimen, which resulted in the greatest gains of plasma Q, with endothelial function being almost normalized. Endothelial function, as measured by the Brachial Artery Reactivity Test, is a non-invasive, preliminary test for cardiovascular disease. The scientists theorized that Q-absorb™ enhanced the endothelial-dependent vasodilation by its effects of reducing ROS (reactive oxygen species), thus resulting in the elevation of nitric oxide.

“One of the important parts of the study was that the 100 milligrams of CoQ10 was taken three times a day,” said Sid Shastri, Vice President, Product Development at Jarrow Formulas. “Three hundred milligrams at one time is a waste because it’s too much for the gut to absorb. We spent several years developing Q-absorb™ and studying its absorption before doing this study. We are confident in our natural formulation and the results were excellent. This is the best CoQ10 study ever done on heart patients.”


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.